Neobavaisoflavone


Catalog No. Size PriceQuantity
M12417-2 2mg solid $110
M12417-10 10mg solid $330

Description

Neobavaisoflavone, a flavonoid, is isolated from the seeds of Psoralea corylifolia. Neobavaisoflavone exhibits anti-inflammatory, anti-cancer and anti-oxidation activities. Neobavaisoflavone inhibits DNA polymerase at moderate to high concentrations. Neobavaisoflavone also inhibits platelet aggregation.

Product information

CAS Number: 41060-15-5

Molecular Weight: 322.35

Formula: C20H18O4

Chemical Name: 7-hydroxy-3-[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]-4H-chromen-4-one

Smiles: CC(C)=CCC1=CC(=CC=C1O)C1=COC2=CC(O)=CC=C2C1=O

InChiKey: OBGPEBYHGIUFBN-UHFFFAOYSA-N

InChi: InChI=1S/C20H18O4/c1-12(2)3-4-14-9-13(5-8-18(14)22)17-11-24-19-10-15(21)6-7-16(19)20(17)23/h3,5-11,21-22H,4H2,1-2H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 31 mg/mL (96.17 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Neobavaisoflavone (1-50 μM; 20 h) decreases NO (ED50=25 μM) and cytokine (ED50s=23.11, 5.03, 5.23, 5.26 and 18.80 μM for IL-1β, IL-6, IL-12p40, IL-12p70 and TNF-α, respectively) production in LPS plus IFN-γ-stimulated RAW264.7 macrophages. Neobavaisoflavone (1-100 μM; 30 min) decreases the chemiluminescence in PMA-stimulated RAW264.7 macrophages, with an ED50 of 19.94 μM in activated RAW264.7 cells. Neobavaisoflavone (1-100 μM); 20 h) has no effect on the viability and is not toxic to RAW264.7 cells. Neobavaisoflavone (20-50 μM; 48 h) inhibits prostate cancer cell proliferation by inducing cytotoxicity and apoptosis in a dose-dependent manner. Neobavaisoflavone (2-8 μM; 7 d) inhibits RANKL‐mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage.

In Vivo:

Neobavaisoflavone (30 mg/kg; i.p. for 6 weeks) inhibits osteoclastogenesis, promotes osteogenesis and ameliorates bone loss in ovariectomized mice.

References:

  1. Szliszka E, et, al. Inhibition of inflammatory mediators by neobavaisoflavone in activated RAW264.7 macrophages. Molecules. 2011 May 3;16(5):3701-12.
  2. Szliszka E, et, al. Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacol Rep. 2011;63(1):139-48.
  3. Chen H, et, al. Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways. J Cell Mol Med. 2020 Aug;24(16):9067-9084.
  4. Sun NJ, et, al. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998 Mar;61(3):362-6.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed